

AUTHOR INDEX

April 15, 1997

- Abedi, M. R., 1523
 Akinaga, S., 1495
 Akiyama, T., 1495
 Andreansky, S., 1502
 Anholt, H., 1481
 Arber, N., 1569
 Archer, G. E., 1510
 Askenazy, N., 1452

 Baird, A., 1447
 Baust, C., 1460
 Beard, S. E., 1575
 Beck, L. A., 1537
 Bell, R. H., Jr., 1475
 Bennett, W. P., 1435
 Bentley, S. A., 1547
 Beraldi, E., 1584
 Berg, K., 1481
 Berger, N. A., 1425
 Bigner, D. D., 1510
 Björkstrand, B., 1523
 Bollag, W., 1460
 Bonfanti, M., 1442
 Borner, C., 1405
 Brecher, M. E., 1547
 Broggini, M., 1442
 Bruchovsky, N., 1584
 Burke, L. M., 1435

 Campaign, J. A., 1447
 Carducci, M. A., 1537
 Chen, A. Y., 1529
 Chen, Z., 1614
 Chou, J., 1502
 Christensson, B., 1523
 Clift, S. M., 1537
 Cohen, L. K., 1537
 Curiel, D. T., 1447

 Dairkee, S. H., 1590
 Darrow, T. L., 1561
 Delohery, T., 1569
 Denk, C., 1460
 Dent, G., 1547
 Di Filippo, F., 1554
 Dilber, M. S., 1523
 D'Incalci, M., 1442
 Doki, Y., 1569
 Douglas, J. T., 1447
 Dragan, Y., 1438
 Dranoff, G., 1537
 Dritschilo, A., 1412
 Dynan, W. S., 1412

 Ecsedy, J. A., 1580
 Englert, C., 1429

 Felding-Habermann, B., 1554
 Ferrone, S., 1554
 Finn, C. C., 1537
 Flotte, E. R., 1502

 Fojo, A. T., 1516
 Frelinger, J. A., 1547
 Furihata, C., 1416

 Gahrton, G., 1523
 Garvin, A. J., 1429
 Gascoyne, R., 1605
 Gaullier, J-M., 1481
 Gee, P., 1575
 Geisen, C., 1460
 Gemma, A., 1435
 Giannarelli, D., 1554
 Gillespie, G. Y., 1502
 Glassman, A. B., 1487
 Gleave, M. E., 1584
 Goldman, C. K., 1447
 Gordon, N. H., 1425
 Gremm, B., 1460

 Haber, D. A., 1429
 Hagiwara, K., 1435
 Hamby, C. V., 1554
 Han, E. K-H., 1569
 Harris, C. C., 1435
 Hauda, K. M., 1537
 Holt, P. R., 1569
 Huang, M-T., 1468
 Hwang, J., 1516

 Ichinose, M., 1416
 Inouye, M., 1468
 Isola, J., 1597
 Ito, T., 1416

 Jaffee, E. M., 1537
 Jiang, S., 1475
 Jordan, V. C., 1438
 Jung, M., 1412

 Kähkönen, M., 1597
 Kallioniemi, A., 1597
 Kallioniemi, O-P., 1597
 Kaplan, O., 1452
 Karger, A., 1460
 Karhu, R., 1597
 Ke, Y., 1435
 Keating, M. J., 1487
 Khan, M. A., 1435
 Kidder, G. M., 1523
 Kim, N-H., 1569
 Klein, M. G., 1569
 Knubovets, T., 1452
 Kopras, E., 1475
 Krajewska, M., 1605
 Krajewski, S., 1605
 Kreidberg, J., 1429
 Kushnir, T., 1452
 Kuukasjärvi, T., 1597

 Lazenby, A. J., 1537
 Lee, M. J., 1575

 Leiferman, K. M., 1537
 Levitsky, H. I., 1537
 Li, D., 1438
 Li, L., 1487
 Liang, B., 1554
 Liu, X-m., 1487
 Ljung, B-M., 1590
 Lo, C-K., 1516
 Lou, Y-R., 1468
 Lu, Y-P., 1468

 Ma, L-W., 1481
 Mackay, W., 1425
 Maheswaran, S., 1429
 Manfredi, M. G., 1580
 Markert, J. M., 1502
 Marshall, F. F., 1537
 McMichael, M., 1475
 Mickley, L. A., 1516
 Miki, K., 1416
 Mirochnitchenko, O. I., 1468
 Mitchell, J. B., 1529
 Mizukami, T., 1495
 Moan, J., 1481
 Moore, D. H., 1590
 Moscatello, D. K., 1419
 Mulligan, R. C., 1537

 Nagashima, M., 1435
 Natali, P. G., 1554
 Naus, C. C. G., 1523
 Navon, G., 1452
 Nelson, W. G., 1537
 Newmark, H. L., 1468
 Nicotra, M. R., 1554
 Nupponen, N., 1597

 Oka, M., 1416
 Okabe, M., 1495
 Okunieff, P., 1529
 Owens, A. H., Jr., 1537

 Pang, D., 1412
 Pardoll, D. M., 1537
 Paulo, E. C., 1590
 Peng, Q., 1481
 Pennanen, S., 1597
 Piantadosi, S., 1537
 Pitot, H. C., 1438
 Plunkett, W., 1487
 Pommier, Y., 1529
 Pourzand, C., 1405

 Ramirez, G., 1419
 Reed, J. C., 1605
 Reelfs, O., 1405
 Reist, C. J., 1510
 Rennie, P. S., 1584
 Reske, K., 1416
 Rogers, B. E., 1447
 Roizman, B., 1502
 Rossier, G., 1405

 Sakaki, Y., 1416
 Salmona, M., 1442
 Sato, N., 1584
 Schäffer, A., 1597
 Schwarz, E., 1460
 Seigler, H. F., 1561
 Selbo, P. K., 1481
 Serody, J. S., 1547
 Seyfried, T. N., 1580
 Sgambato, A., 1569
 Shabaik, A., 1605
 Shea, T. C., 1547
 Shillitoe, E. J., 1614
 Shimizu, M., 1495
 Siegal, G. P., 1447
 Simons, J. W., 1537
 Smith, C. I. E., 1523
 Smith, H. S., 1590
 Soroceanu, L., 1502
 Sosnowski, B. A., 1447
 Storthz, K. A., 1614
 Stros, M., 1487
 Su, J-S., 1516
 Sullivan, L. D., 1584

 Tanner, M., 1597
 Tatematsu, M., 1416
 Taverna, S., 1442
 Temponi, M., 1554
 Ting, C-Y., 1516
 Traquina, P., 1590
 Tsujita, T., 1495
 Tyrrell, R. M., 1405

 Ulrich, C. D., II, 1475

 Wang, H-G., 1605
 Wang, L-F., 1516
 Wang, M., 1438
 Weber, C. E., 1537
 Weinstein, I. B., 1569
 Whang-Peng, J., 1516
 Whitacre, C. M., 1425
 Whitley, R. J., 1502
 Wikstrand, C. J., 1510
 Wong, A. J., 1419

 Yamamoto, M., 1416
 Yang, L-Y., 1487
 Yang, S., 1561
 Yen, P., 1468
 Ying, W., 1447
 Yohe, H. C., 1580
 Yoo, S., 1412
 Yoshida, T., 1495

 Zalutsky, M. R., 1510
 Zapata, J. M., 1605
 Zborowska, E., 1425
 Zhou, P., 1569

METHODS IN CLINICAL CANCER RESEARCH

Second Annual Workshop Co-Sponsored by

THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO)


and

THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR)



*An Outstanding Opportunity for Researchers
at the Level of Clinical Fellow or Junior Faculty
to Learn the Essentials of Clinical Trials Design*

July 26-August 1, 1997, Vail Cascade Hotel & Club, Vail, Colorado



Supported by a Major Grant from the National Cancer Institute and Generous Contributions from
Amgen, Inc., Bristol-Myers Squibb Oncology, and Hoechst Marion Roussel

PROGRAM COMMITTEE

ASCO

Charles A. Coltman, Jr., Chairperson
Janice P. Dutcher
Michael A. Friedman
Steven Piantadosi
Mark J. Ratain

AACR

Daniel D. Von Hoff, Chairperson
David S. Alberts
Gary M. Clark
Merrill J. Egorin
Sandra J. Horning

SCIENTIFIC PROGRAM

Workshop Goals. Errors made in the design and conduct of clinical trials can make it impossible for the trial to provide a definitive answer about the effectiveness of a new approach. Poor design can thus lead to the abandonment of promising avenues of research that are based on sound basic scientific work and to delays in the introduction of new treatments into the general practice of medical oncology. ASCO and AACR have responded to this problem by designing a program that will

(1) Introduce clinical fellows in any oncology subspecialty as well as some more senior oncologists to the principles of good clinical trials design; *i.e.*, give them the tools they need to conduct clinical trials that will yield clear results which investigators can use to proceed to the next level of research.

(2) Expose young clinical scientists to the full spectrum of challenges in clinical research, from conventional antineoplastics to gene therapy, in the expectation that they will then want to devote all or a portion of their future careers to some aspect of clinical research.

(3) Develop a cadre of well-trained, experienced researchers whose expertise will foster better clinical trials design and thereby hasten the introduction of improved agents for cancer therapy and prevention into everyday medical practice and patient care.

Scientific Session Formats. The workshop scientific program will consist of three types of activities to serve a variety of didactic needs:

Lectures on specific topics presented by experts in the field to give participants a necessary overview of the field.

Small Group Discussion Sections on certain topics such as measures of outcome, combined modality trials, and inclusion of special populations that are essential to the success of many different kinds of clinical trials. Groups of 10-20 students will meet with a team of experienced faculty members to obtain this practical training. Each section will be repeated three times during the workshop.

Protocol Development Sessions during which each participant develops a concept sheet for a clinical trial protocol. This exercise will allow

students to apply the lessons being learned in the workshop to their own programs and to receive detailed critiques of their proposals from experienced scientists.

FACULTY MEMBERS

David S. Alberts, Arizona Cancer Center, Tucson, AZ
Otis W. Brawley, National Cancer Institute, Rockville, MD
Gary M. Clark, University of Texas Health Science Center, San Antonio, TX
Jerry M. Collins, U.S. Food and Drug Administration, Rockville, MD
Charles A. Coltman, Jr., Cancer Therapy and Research Foundation of South Texas, San Antonio, TX
John J. Crowley, Fred Hutchinson Cancer Research Center, Seattle, WA
Janice P. Dutcher, Albert Einstein College of Medicine, Bronx, NY
Merrill J. Egorin, University of Maryland Cancer Center, Baltimore, MD
Ellen G. Feigal, National Cancer Institute, Bethesda, MD
Stephen L. George, Duke University Medical Center, Durham, NC
M. Margaret Kemeny, North Shore University Hospital, Manhasset, NY
John H. Littlefield, University of Texas Health Science Center, San Antonio, TX
Albert F. LoBuglio, University of Alabama Comprehensive Cancer Center, Birmingham, AL
H. Kim Lyerly, Duke University Medical Center, Durham, NC
Wayne L. Monsky, Beth Israel-Deaconess Hospital, Boston, MA
Gina P. Petroni, University of Virginia School of Medicine, Charlottesville, VA
Steven Piantadosi, Johns Hopkins Oncology Center, Baltimore, MD
Mark J. Ratain, University of Chicago, Chicago, IL
Paul Sondel, University of Wisconsin Clinical Science Center, Madison, WI
G. Marie Swanson, Michigan State University Cancer Center, East Lansing, MI
Ian F. Tannock, Princess Margaret Hospital, Toronto, Ontario, Canada
Daniel D. Von Hoff, Institute for Drug Development, San Antonio, TX
Robert E. Wittes, National Cancer Institute, Bethesda, MD

Daily Calendar

Day 1 — Saturday, July 26, 1997

12:00 noon – 8:00 pm	Registration
4:00 – 5:00 pm	Administration of Pretest
5:00 – 5:30 pm	Welcome and Overview of
	Workshop
5:30 – 7:00 pm	Introduction

New Technologies, New Challenges for Clinical Trial Design.
 Caboom: The Pitfalls of Clinical Trials.

7:00-10:00 pm Reception and Dinner

Day 2 — Sunday, July 27, 1997

8:30 – 11:45 am **Morning Session**

Principles of Selecting an Important and Accomplishable Clinical Research Question.
 Basic Biostatistics for the Clinical Trialist I
 Basic Biostatistics for the Clinical Trialist II

1:00 – 4:00 pm **Protocol Development Session I
 (Establish the Problem)**

Remainder of Day Free with Computers Available for Students to Draft Protocols

Day 3 — Monday, July 28, 1997

8:30 am – 12:00 noon **Morning Session**

Preclinical Development of New Agents
 Regulatory Issues in the Development of a New Antitumor Agent
 The Phase I Clinical Trial
 Examples of Excellent Laboratory Correlates in Clinical Trials

1:00 – 3:00 pm **Afternoon Session**

Principles of Clinical Pharmacology
 Principles of Pharmacodynamics
 Pharmacology-Panel Discussion

3:00 – 6:00 pm **Protocol Development Session II
 (Review of Initial Drafts)**

8:00 – 11:00 pm **Evening Session**

Case Problems for Ethical Principles in Clinical Trials
 Discussion Sections on Ethics in Clinical Trials

Day 4 — Tuesday, July 29, 1997

8:30 – 10:30 am **Morning Session**

The Art of the Elegant Phase II Trial
 Phase III Trial Designs: The Best and the Challenges

11:00 am – 1:00 pm **Protocol Consultation Session**

Remainder of Day Free with Computers Available for Students to Develop Protocols

Day 5 — Wednesday, July 30, 1997

8:30 – 10:00 am
 10:30 am – 12:00 noon

Small Group Discussion Session #1
Small Group Discussion Session #2

Remainder of Day Free with Computers Available for Students to Complete Protocols

Day 6 — Thursday, July 31, 1997

8:30 am – 12:00 noon **Morning Session**

Controversies in Biostatistics I
 Controversies in Biostatistics II
 Epidemiology and Clinical Trials
 Special Considerations for Surgical Oncology Trials

1:00 – 3:15 pm **Afternoon Session**

Special Considerations for Pediatric Oncology Trials
 Special Considerations for Radiation Oncology Trials
 Special Considerations for the Design of Prevention Trials

2:30 – 4:00 pm	Small Group Discussion Session #3
4:00 – 5:00 pm	Administration of Post-test
6:00 – 7:00 pm	Protocol Discussion Group
7:30 – 11:00 pm	Reception and Banquet

Day 7 — Friday, August 1, 1997

Departure

Small Group Discussion Topics

- A. New Measures of Outcome, Quality of Life, Clinical Benefit, Cost Benefit
- B. Special Problems in Clinical Trial Design – Cytostatic Agents, Angiogenesis Inhibitors, Growth Factors
- C. Special Problems in the Design of Clinical Trials with Biologics
- D. Teaching Skills
- E. Women and Special Populations
- F. The Challenge of Combined Modality Trials
- G. Special Design Problems in Gynecologic and Urologic Oncology Trials
- H. Design of Clinical Trials for Patients with HIV-related Malignancies

APPLICATION PROCEDURE

1. Complete the attached Application Form.
2. Submit a letter explaining why you wish to participate in this workshop. Be sure that your letter provides the following information:
 - a. A description of your previous research background.
 - b. The nature of the program in which you are scheduled to participate for the next two years.
 - c. A description of the kind of program in which you would like to be working in five years.
 - d. A brief summary of the clinical trial design problem you intend to address in the protocol concept sheet you will develop at the workshop. Example: "Will an antisense to HER-2/neu increase the antitumor activity of cisplatin?" NOTE: At the workshop applicants may address a different problem but these responses will be used to assign participants to appropriate faculty advisors.
 - e. An explanation of how participation in the workshop will help you to design and conduct the trial to be outlined in your protocol.

f. A commitment to participate in the long-term evaluation of this workshop by maintaining contact with the organizers and responding to questionnaires when requested.

3. Submit a letter from your Program Supervisor or Department Head in support of your application for this workshop. This letter should include the following:

- a. A description of the length of time and the capacity in which the writer has known the applicant.
- b. An assessment of the quality of the applicant's performance in his or her current program.
- c. A commitment to make every reasonable effort to enable the candidate to conduct a clinical trial based on the concept sheet produced at the workshop.
- d. A commitment to participate in the long-term evaluation of this workshop by reporting the results of the trial conducted by the candidate to the organizers and by responding to questionnaires that may be submitted by the organizers.

4. The deadline for submission of applications is **April 30, 1997**.

GENERAL INFORMATION

Selection of Participants. The Organizing Committee will review applications and accept participants from applications received from **fellows** and **junior faculty** as described below. The Committee will base its decisions in large part on the letters submitted by the applicant and the sponsor. These documents will be scrutinized both for the information they supply about the candidate and the assurances they provide about the participation of the candidate and his or her sponsor in the long-term evaluation of the workshop. Applicants will be notified of their status by early June 1997.

Fellows. The Committee will award scholarships to 75 applicants who are clinical fellows in any oncology subspecialty. Applicants will be selected on the basis of letters of application from the individuals and letters of nomination from their supervisors or heads of departments. The Committee will seek a group of trainees who have made outstanding progress in their medical training, who have displayed an interest and competence in clinical cancer research, and who will come from a diverse group of training institutions and personal backgrounds. Applications from female and minority scientists are encouraged.

The 75 participants selected from this group will not be required to pay any registration fee for the workshop. They will also receive complimentary airline tickets, hotel accommodations in Vail for the nights of July 26 through July 31, inclusive, and complimentary meals throughout the workshop. Participants receiving scholarships will be required to share sleeping rooms with other awardees. An activity fee of \$75 will be imposed on all participants to offset the costs of social events and certain group meals.

Junior Faculty. The Committee will also admit to the course 25 clinical scientists who have already embarked on academic careers, who hold an

appointment at the level of Assistant Professor or below, and who completed their fellowships after April 30, 1992. These scientists will not be required to pay a registration fee for the workshop, although they will be required to pay a \$75 activity fee. Junior faculty will also receive complimentary meals throughout the workshop and a stipend of \$600 to support their travel and subsistence costs.

Workshop Materials. All faculty members will contribute material to the workshop syllabus to be distributed to all participants in advance of the workshop. For each lecture and small group discussion section the syllabus will contain the instructional objectives of the presentation, an outline of the topics to be covered, and a bibliography of relevant articles and texts.

Continuing Medical Education.

The American Society of Clinical Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians.

The American Society of Clinical Oncology designates this continuing medical education activity for up to 32 credit hours in Category I towards the AMA Physicians Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Workshop Site. Workshop sessions will take place at the Vail Cascade Hotel & Club, Vail, Colorado. While Vail is particularly famous for its outstanding skiing, a full complement of summer recreational activities including hiking, golfing, fishing, and swimming are available a short distance from the Hotel. In addition, workshop participants will be able to use the well-equipped Cascade Athletic Club, which offers a variety of spa and recreation facilities including indoor/outdoor tennis, racquetball, squash, basketball, aerobics, nautilus equipment, steam rooms, whirlpools, and more.

The Organizers will arrange for complimentary shuttle bus transportation for workshop participants between the Denver International Airport and the Vail Cascade Hotel on Saturday afternoon, July 26, and again on Friday morning, August 1. Those admitted to the workshop will receive the schedule of these special buses, which are the only buses on which complimentary transportation will be provided.

Workshop Housing. All applicants accepted to the workshop must reside at the Vail Cascade Hotel & Club for the duration of the workshop and participate in all group meals. **Fellows** will receive the following complimentary accommodations at the hotel: a hotel room to be shared with one other workshop participant and three meals each day beginning with dinner on Saturday, July 26 and concluding with breakfast on Friday, August 1. **Fellows** requesting other accommodations at the Vail Cascade Hotel will be reimbursed only for the amount ASCO and AACR would have been charged for the complimentary accommodations (approximately \$80 per day).


The following accommodations are available to **junior faculty**:

Standard Rooms	\$160.00
Deluxe Rooms	\$185.00
One-Bedroom Suites	\$275.00

All of the above prices, per room per night, are based on single or double occupancy.



AMERICAN SOCIETY OF CLINICAL ONCOLOGY
AMERICAN ASSOCIATION FOR CANCER RESEARCH



APPLICATION FORM

METHODS IN CLINICAL CANCER RESEARCH: A WORKSHOP

(Please Print or Type)

NAME _____
Last First

M.I.

TYPE OF APPLICATION Applicant is a (check only **one** of the two boxes below and supply the date requested)

- ☐ oncology fellow seeking waiver of registration fees and support for travel and housing for this workshop. Anticipated date of completion of current fellowship: _____
- ☐ clinical scientist at the junior faculty level (Assistant Professor or below; fellowship completed after April 30, 1992) who will receive complimentary meals and a stipend of \$600 towards travel and housing Date of completion of last fellowship: _____

CURRENT POSITION TITLE _____

INSTITUTION _____

INSTITUTIONAL ADDRESS _____

City State/Province/Country Postal Code

TELEPHONE _____ **FAX** _____ **E-MAIL** _____

HAVE YOU ATTENDED A RELATED OR SIMILAR COURSE? ____ Yes ____ No. If yes, please describe:

EDUCATION (Begin with baccalaureate or other initial professional degree)

Degree Institution City State or Country Year

Degree Institution City State or Country Year

Degree Institution City State or Country Year

Degree Institution City State or Country Year

PUBLICATIONS [List the authors, title, journal, volume, inclusive pages, and year of any article in a *peer-reviewed clinical or basic scientific journal* on which you appear as an author (if any). *Do not list abstracts.* Continue on a separate sheet if necessary.]

ASSURANCES AND SIGNATURES This form must be signed where indicated by both the applicant and the supervisor submitting a letter of recommendation.

Applicant: I certify that the above statements are true and complete to the best of my knowledge. If admitted to the workshop, I agree to attend all scheduled sessions and afterwards to participate as requested in the long-term evaluation of this program.

Signature

Date

Sponsor of Applicant: I recommend this applicant for the ASCO/AACR Workshop on Methods in Clinical Cancer Research. I certify that the above statements are true and complete to the best of my knowledge. If the applicant is admitted, I agree to make every reasonable effort to enable the candidate to conduct a clinical trial based on the protocol concept sheet developed at the workshop and to participate as requested in the long-term evaluation of this program.

Signature

Date

Submit this application form, letter of application from the candidate, and letter of support from the candidate's supervisor or department head **no later than April 30, 1997**, to:

Methods in Clinical Cancer Research
American Society of Clinical Oncology
225 Reinekers Lane, Suite 650
Alexandria, VA 22314
(703) 299-1070 • Telephone
(703) 299-1044 • FAX



AMERICAN ASSOCIATION FOR CANCER RESEARCH

GUIDELINES FOR APPLICATION FOR ACTIVE AND CORRESPONDING MEMBERSHIP

BENEFITS OF MEMBERSHIP

The American Association for Cancer Research (AACR), a scientific society of over 11,500 laboratory and clinical cancer researchers, was founded in 1907 to facilitate communication and dissemination of knowledge among scientists and others dedicated to the cancer problem; to foster research in cancer and related biomedical sciences; to encourage the presentation and discussion of new and important observations in the field; to foster public education, science education, and training; and to advance the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world.

Members of the AACR enjoy the following benefits:

1. the privilege of sponsoring a proffered paper (abstract) for consideration for presentation at the AACR annual meeting;
2. an advance copy of the Program and *Proceedings of the American Association for Cancer Research* that contains over 4,000 abstracts of proffered papers presented at the annual meeting;
3. reduced registration rates at annual meetings;
4. priority notice of small, focussed meetings in the AACR's exciting series of Special Conferences in Cancer Research;
5. substantially reduced registration rates for Special Conferences;
6. opportunities for participation in AACR meetings in North America and abroad with other scientific societies around the world;
7. receipt of AACR Newsletters and other important announcements;
8. early notification of and reduced rates for participation in the AACR Employment Register;
9. an up-to-date Membership Directory of over 11,500 member researchers in the cancer field;
10. the professional benefits of the AACR's public education activities concerning funding for cancer research and press coverage of the latest research findings;
11. the opportunity to participate in three Summer Workshops that foster knowledge in the cancer field for young investigators;
12. the facilitation of informal scientific exchange with leading researchers in the cancer field; and
13. many more ongoing benefits.

QUALIFICATIONS FOR MEMBERSHIP

Active membership in the AACR is open to investigators who live in the Americas. Individuals who have conducted two years of research resulting in peer-reviewed publications relevant to cancer, or who have made substantial contributions to cancer research in an administrative or educational capacity, are eligible. If a candidate has conducted research in an area of biomedical science related to cancer, he or she will qualify for membership. Evidence of patents relevant to cancer research may be submitted as qualifications for membership in lieu of peer-reviewed publications.

Corresponding membership is open to persons who are not residents of the Americas. The qualifications for corresponding membership are the same as those indicated above for active membership. Visiting scientists from outside the Americas who intend to return to their countries of origin by the anticipated time of election should apply for corresponding membership. All other visiting scientists should apply for active membership and transfer to corresponding status upon leaving the Americas.

Graduate and medical students, postdoctoral fellows, and physicians in training who do not yet meet the above qualifications for active or corresponding membership should apply for **associate** membership. Forms for associate membership are available from the AACR Office.

PROCEDURES FOR APPLICATION

There are three deadlines for the receipt of a membership application: January 1, May 1, and September 1 of each year. The Membership Committee will review all complete applications for active membership that have been received by these deadlines and will submit recommendations on each candidate to the Board of Directors which formally elects all members. The same procedure is followed by the Special Memberships

Committee which receives applications for corresponding membership. Candidates will be notified according to the following schedule:

Receipt of Application in AACR Office	Notification of Candidate
January 1	March
May 1	July
September 1	November

A complete application consists of the following material:

1. 6 copies of the form on the opposite side of this page, with all requested information provided.
2. 5 copies of the candidate's most current curriculum vitae and bibliography.
3. 5 copies of a letter of recommendation from a nominator who is an active, corresponding, emeritus, or honorary member of the AACR (at least one copy must be a signed, original letter). This letter should describe the candidate's achievements in laboratory research, clinical investigations, or epidemiological research, and it should affirm that this research adheres to accepted ethical scientific standards. -OR- The nominator may supply the responses requested at the bottom of the application form in the section entitled "STATEMENT OF SUPPORT" (at least one copy of the form must be the signed original).
4. 5 copies of a letter of recommendation as described in Item 3 above from a seconder who is an active, corresponding, emeritus, or honorary member of the AACR (at least one copy must be a signed, original letter). -OR- The seconder may supply the responses requested at the bottom of the application form in the section entitled "STATEMENT OF SUPPORT" (at least one copy of the form must be the signed original).
5. 5 reprints of each of two publications on which the candidate appears as author. As noted above, evidence of patents developed by the candidate may be submitted in lieu of one or both of the publications. If submitting patents, supply patent number and year awarded.

All material should be collated into five complete sets with the original application form as a covering document and sent to the address given below. Questions regarding procedures for membership application may also be directed to the following address:

American Association for Cancer Research
Public Ledger Building, Suite 826
150 S. Independence Mall West
Philadelphia, PA 19106-3483
Phone: 215/440-9300
FAX: 215/440-9313
E-mail: aacr@aacr.org

RESPONSIBILITIES OF MEMBERSHIP

Candidates should be aware of the following responsibilities of membership in the AACR. Active members must pay annual dues. In 1997 annual dues for active members are \$175, \$100 of which is designated for AACR journal subscriptions. Newly elected members of the AACR who have already purchased subscriptions to *Cancer Research*, *Clinical Cancer Research*, *Cell Growth & Differentiation*, or *Cancer Epidemiology, Biomarkers & Prevention* at the higher, nonmember rates will receive reimbursement of the unused portion of those subscriptions once their first year's membership dues are paid in full.

Corresponding members are required to pay dues (\$90 in 1997) and may, if they wish, subscribe to *Cancer Research*, *Clinical Cancer Research*, *Cell Growth & Differentiation*, or *Cancer Epidemiology, Biomarkers & Prevention* at reduced member rates.

Applicants elected in March will be responsible for payment of that year's dues; applicants elected in July and November will pay dues for the following year. Applicants elected in March and July will be eligible to sponsor an abstract for the next annual meeting. Every effort will be made to afford the same opportunity to applicants elected in November.

Margaret Foti, Ph.D.
Executive Director

AMERICAN ASSOCIATION FOR CANCER RESEARCH, INC.

Public Ledger Building • Suite 826 • 150 S. Independence Mall West • Philadelphia, PA 19106-3483



APPLICATION FOR ACTIVE OR CORRESPONDING MEMBERSHIP

NAME OF CANDIDATE: _____ DATE OF BIRTH: _____
LAST FIRST M.I.

PRESENT POSITION/TITLE: _____

INSTITUTIONAL AFFILIATION: _____

INSTITUTIONAL ADDRESS: _____

(City) (State/Province) (Country) (Postal Code)

TELEPHONE NUMBER: _____ FAX NUMBER: _____

E-MAIL NUMBER (CARRIER): _____

PRIMARY FIELD OF RESEARCH (Please check only one):

<input type="checkbox"/> Biochemistry and Biophysics	<input type="checkbox"/> Biostatistics	<input type="checkbox"/> Carcinogenesis
<input type="checkbox"/> Cellular Biology and Genetics	<input type="checkbox"/> Clinical Investigations	<input type="checkbox"/> Endocrinology
<input type="checkbox"/> Epidemiology	<input type="checkbox"/> Immunology	<input type="checkbox"/> Molecular Biology and Genetics
<input type="checkbox"/> Preclinical Pharmacology and Experimental Therapeutics	<input type="checkbox"/> Virology	<input type="checkbox"/> Other: _____ (Please specify)

ACADEMIC DEGREES (Including where and when granted)

EXPERIENCE SINCE HIGHEST DEGREE WAS GRANTED (Please list most recent first)

PUBLICATIONS (Reprints of two peer-reviewed articles on which the candidate appears as an author must accompany this application. For these two articles list the authors, title, journal, volume, inclusive pages, and year. Do not submit abstracts. If submitting patents, supply patent number and year awarded.)

CANDIDATE IS APPLYING FOR (Check one): ☐ ACTIVE ☐ CORRESPONDING MEMBERSHIP

CANDIDATE NOMINATED BY*: _____ CANDIDATE SECONDED BY*: _____
(Please print) (Please print)

STATEMENT OF SUPPORT

Instead of submitting letters of recommendation, either the nominator or the seconder or both may complete the following section:

I acknowledge by signing this statement of support that this candidate adheres to accepted ethical scientific standards and has or will make a long-term contribution to cancer research.

Signature of Nominator* _____ Date _____ Signature of Seconder* _____ Date _____

See Guidelines for Application on the reverse side of this form for further instructions.

*Both nominator and seconder must be active, corresponding, emeritus, or honorary members of the AACR.



AMERICAN ASSOCIATION FOR CANCER RESEARCH

GUIDELINES FOR APPLICATION FOR ASSOCIATE MEMBERSHIP

QUALIFICATIONS FOR MEMBERSHIP

Associate membership is open to graduate students, medical students, postdoctoral fellows, and physicians in training who are following a course of study or who are working in a research program relevant to cancer. Scientists in training who already have a substantial record of publications may wish to apply for active or corresponding membership which confers full benefits of membership.

BENEFITS OF MEMBERSHIP

The American Association for Cancer Research (AACR), a scientific society consisting of laboratory and clinical cancer researchers, was founded in 1907 to facilitate communication and dissemination of knowledge among scientists and others dedicated to the cancer problem; to foster research in cancer and related biomedical sciences; to encourage presentation and discussion of new and important observations in the field; to foster public education, science education, and training; and to advance the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world. Associate members of the AACR enjoy the following benefits:

1. the privilege of sponsoring a proffered paper (abstract) for consideration for presentation at the AACR annual meeting provided that (a) the associate member is the presenter of the paper and (b) an active, corresponding, emeritus, or honorary member in good standing of the AACR also signs the abstract of the paper in support of the work. (In this instance, the member who cosigns the abstract does not lose his or her own sponsorship privilege.);
2. an advance copy of the scientific Program and (if one has been purchased by the associate member) the *Proceedings of the American Association for Cancer Research* that contains over 4,000 abstracts of proffered papers presented at the annual meeting;
3. the privilege of registering for the annual meeting at the low associate member rate;
4. preferred access to the AACR Employment Register;
5. optional subscriptions to the Association's high-quality journals *Cancer Research*, *Clinical Cancer Research*, *Cell Growth & Differentiation*, and *Cancer Epidemiology, Biomarkers & Prevention* at reduced member rates;
6. priority notification of events in the AACR's series of special conferences on timely subjects in the field;
7. substantially reduced registration rates at special conferences;
8. the receipt of AACR newsletters, meeting announcements, and an up-to-date Membership Directory;
9. the opportunity to participate in three Summer Workshops that foster knowledge in the cancer field for young investigators; and
10. the facilitation of informal scientific exchange with leading researchers in the cancer field.

PROCEDURES FOR APPLICATION

Persons wishing to apply for associate membership must use the official application form on the reverse side of these instructions. Each candidate for associate membership must be nominated by an active, corresponding, emeritus, or honorary member in good standing of the AACR. Three completed copies of the form should be submitted; at least one of these copies must carry the original signatures of both the candidate

and the nominator. In addition, the candidate should submit one copy of his or her curriculum vitae. The application form may be submitted to the Association Office at any time.

After review of applications for associate membership, the Executive Director will notify candidates of their election or deferral within one month of the receipt of the application form. A check for one year's dues payment must accompany the application. Dues for 1996 are \$35 for associate members residing in the Americas and \$45 for residents of other countries. For 1997 these rates are \$45 and \$55, respectively. This fee will be refunded to any candidate deemed to be ineligible for associate membership. Checks should be in U.S. currency, made payable to AACR, Inc., and drawn on a U.S. bank. Send the three copies of the application form and the appropriate dues payment to:

American Association for Cancer Research
Public Ledger Building, Suite 826
150 S. Independence Mall West
Philadelphia, PA 19106-3483
Phone: 215/440-9300
FAX: 215/440-9313
E-mail: aacr@aacr.org

RESPONSIBILITIES OF MEMBERSHIP

Associate members must pay annual dues in an amount to be determined by the AACR Board of Directors. Dues for 1996 have been set at \$35 per year for residents of the Americas and \$45 for residents of other countries. For 1997 these rates are \$45 and \$55, respectively. If an application is submitted by August 31, the accompanying dues payment will be credited to the current year. Candidates submitting applications between September 1 and December 31 may indicate whether they wish their dues payments credited to the current or forthcoming year. Candidates should be aware, however, that associate members may sponsor an abstract for the annual meeting only if their dues for the current year are paid. For example, an associate member submitting an abstract in November 1996 for the forthcoming annual meeting must have paid dues for 1996. Any newly elected associate members of the AACR who have already purchased subscriptions to *Cancer Research*, *Clinical Cancer Research*, *Cell Growth & Differentiation*, or *Cancer Epidemiology, Biomarkers & Prevention* at the higher, nonmember rate will receive a refund for the unused portion of that subscription upon receipt of their payment for a member's subscription.

Each Fall the AACR will send to current associate members an invoice for dues for the forthcoming year. Payment of this invoice must be accompanied by a statement signed by the associate member's current registrar, dean, or department head, verifying the member's current academic status. The Association's By-Laws state that dues are payable for each year in advance by January 1 of the year to which they should be applied. An individual may be an associate member for a maximum of five years. Each year in which an individual pays dues will count as one full year of associate membership. Thus, an associate member who pays dues for 1996 may retain associate membership until December 31, 2000. The Board of Directors may terminate the membership of an associate member whose dues are in arrears for two years.

Margaret Foti, Ph.D.
Executive Director

AMERICAN ASSOCIATION FOR CANCER RESEARCH, INC.

Public Ledger Building • Suite 826 • 150 S. Independence Mall West • Philadelphia, PA 19106-3483



APPLICATION FOR ASSOCIATE MEMBERSHIP

NAME OF CANDIDATE: _____ DATE OF BIRTH: _____
LAST FIRST M.I.

INSTITUTIONAL AFFILIATION: _____

INSTITUTIONAL ADDRESS: _____

(City) (State/Province) (Country) (Postal Code)

TELEPHONE NUMBER: _____ FAX NUMBER: _____

PRESENT ACADEMIC STATUS/TITLE (Please check only one): E-MAIL NUMBER (CARRIER): _____

____ Graduate Student ____ Medical Student
____ Physician in Training ____ Postdoctoral Fellow

PRIMARY FIELD OF RESEARCH (Please check only one):

____ Biochemistry and Biophysics ____ Biostatistics ____ Carcinogenesis
____ Cellular Biology and Genetics ____ Clinical Investigations ____ Endocrinology
____ Epidemiology ____ Immunology ____ Molecular Biology and Genetics
____ Preclinical Pharmacology and ____ Virology ____ Other: _____
Experimental Therapeutics

(Please specify)

ACADEMIC DEGREES (Please indicate degree(s) acquired to date along with the name of the academic institution and date of receipt. Provide information on degree currently being sought and the anticipated date of completion of this degree program.)

RELEVANT RESEARCH EXPERIENCE NOT RELATED TO COURSE WORK (Please list most recent first.)

PUBLICATIONS (List the authors, title, journal, volume, inclusive pages, and year of any article in a peer-reviewed journal on which the candidate appears as an author. Do not list abstracts. Continue on a separate sheet, if necessary.)

CANDIDATE NOMINATED BY*: _____

(Please print)

SIGNATURES

I hereby apply for associate membership in the American Association for Cancer Research. I have read the instructions on the reverse side of this form, and I understand the privileges and responsibilities of this class of membership. I certify that the statements on this application are true.

Signature of Candidate: _____ Date: _____

I recommend this candidate for associate membership in the American Association for Cancer Research. To the best of my knowledge, the candidate is qualified for this class of membership, and the statements on this application are true.

Signature of Nominator*: _____ Date: _____

Submit three copies of this form. At least one copy must contain the original signatures of the candidate and the nominator. In addition, submit one copy of your curriculum vitae. Enclose a check in U.S. funds, made payable to AACR, Inc., and drawn on a U.S. bank for one year's dues. For 1996, dues are \$35 for associate members residing in the Americas and \$45 for residents of other countries. For 1997, these rates will be \$45 and \$55, respectively.

Check one of the following boxes only if this form is being submitted between September 1 and December 31:

The enclosed dues payment should be applied to the ☐ current ☐ forthcoming calendar year.

(NOTE: If dues are applied to the forthcoming year, membership will take effect on January 1, but the candidate will not be eligible to sponsor an abstract for presentation at the annual meeting in March or April of that year.) See Guidelines for Application on the reverse side of this form for further instructions.

*Nominator must be active, corresponding, emeritus, or honorary member of the AACR.

(This form may be reproduced.)

1997

Guidelines for Submitting Disks to American Association for Cancer Research Publications

The word processing packages that we prefer are as follows:

MacWrite	WordPerfect (DOS, Windows,
Microsoft Word (DOS, Windows,	and Macintosh)
and Macintosh)	XyWrite (DOS and Windows)

Also acceptable:

Ability	Mass 11	SoloWriter
AmiPro	MS Windows Write	Sprint
A _M S-TeX	MS Works	Stx
Appleworks	MS Works WP Mac	SunWrite
ArborTeX	Multimate	Symphony
ArborText	Multimate Advantage	TEX
ClarisWorks WP	Nibia	TeX78
CPT 8000	Nisus (to ASCII file)	Text EXecutive
CTOS	Notewriter	Textures
Diablo	Obun	Total Word
DisplayWrite	OfficeWriter	Troff
Duet	PC Write	μTeX
Einstein	PFS First Choice	Volkswriter
Enable	Professional Write	VuWriter
EXP	Q&A Write	Wang OIS
Final Word	Quark XPress	Wang WPS
FullWrite	RagTime MS Works	Wang Writer
GemWord Plus	(to ASCII file)	Window Works
IBM Writing Assistant	Rich Text Format	Windows Write
Interleaf	RSG (to ASCII file)	WiziWord
LaTeX	Signature	Wordstar
Latex	SLiTeX	Wordstar 2000
Leading Edge	SmartWhere	WriteNow
Lotus Manuscript	SmartWrite II	Xerox
Lotus Write		

Software packages that we are unable to translate:

FrameMaker	Ready, Set, Go
PageMaker	Scientific Writer

Disks produced on IBM or IBM-compatible computers are preferred, but those produced on some Apple or Wang computers can also be converted. Because of the file structures and internal coding, we cannot accept disks created on desktop publishing systems or those created on proprietary typesetting systems. We also cannot guarantee that all special characters can be translated. Tabular and mathematical material, such as equations, will not be captured from the disk but will be rekeyed.

To expedite work and for your own security, we do require that you submit a hard copy printout of the disk file. The tables and equations will be keyed from this hard copy. We also need to know the name of the file to be converted, the type of hardware (e.g., IBM PC) on which the files were created, the operating system (e.g., DOS 3.3), and the version of the software (e.g., WordPerfect 5.1) used to create the file.

<p>PLEASE FILL OUT ALL INFORMATION ON REVERSE SIDE AND SUBMIT THIS FORM WITH YOUR DISK. DISKS WILL NOT BE PROCESSED WITHOUT THIS INFORMATION.</p>



DISK SUBMISSION FORM

AACR journals are now using personal computers to copyedit manuscripts accepted for publication. When submitting a revised manuscript, authors are encouraged to submit an electronic disk of the paper along with the required four hard copy printouts. Disks will ultimately be returned to the authors.

See reverse for the word processing packages that can be accepted.

File preparation

Please be sure that the file you send is the most recent version of the manuscript and that it matches the most recently submitted printed copy. The file should contain all the parts of the manuscript in **one** file. Mathematical and tabular material, however, will be processed in the traditional manner and may be excluded from the disk file.

Note: AACR does not assume responsibility for errors in conversion of customized software, newly released software, or special characters.

Please label the outside of the disk with the journal name, the first author's name, a partial title of the manuscript, and the name of the computer file used to access the manuscript on disk. To process your disk efficiently, we need the following information. Please be sure to provide **ALL** the information.

Name used to access paper on disk: _____

Name of computer used (e.g., IBM/PS2): _____

Operating system and version (e.g., DOS 3.3): _____

Word processing program and version (e.g., WordPerfect 5.0): _____

[See reverse for acceptable programs.]

Manuscript number: _____

First author: _____

Corresponding author (if different from first author): _____

Telephone/FAX numbers: _____

This form (both sides) may be reproduced.

1997 Elion Award and AACR Research Fellowships

The American Association for Cancer Research is proud to announce the winners of the 1997 Gertrude B. Elion Cancer Research Award and the 1997 AACR Research Fellowships. The Elion Awardee was selected from among 45 applicants, while the six Research Fellows were selected from nearly 200 applicants. The sponsors of these awards and the titles of the awardees' research projects are listed below.

Jeffrey L. Wrana, Ph.D.

Gertrude B. Elion Cancer Research Award

Sponsored by Glaxo Wellcome Oncology

"Function of the Tumour Suppressor Gene, MADR2, in Cancer"

Mary-Jane Staba, M.D.

AACR Research Fellowship in Clinical or Translational Research

Sponsored by Amgen, Inc.

"Mechanisms of Radiosensitization of Adenovirus TNF Gene Therapy in Malignant Gliomas"

Michael Girardi, M.D.

AACR Research Fellowship in Clinical Research

Sponsored by Bristol-Myers Squibb Oncology

"DNA Immunization for T Cell Lymphoma"

Joseph Bokar, M.D., Ph.D.

AACR Research Fellowship in Basic Research

Sponsored by the American Association for Cancer Research

"Function of N⁶-Adenosine Methyltransferase in Cancer Cells"

Joseph F. Costello, Ph.D.

AACR Research Fellowship in Basic Research

Sponsored by Hoechst Marion Roussel

"Two Dimension Genome Scanning of Human Gliomas"

Hong-Gang Wang, Ph.D.

AACR Research Fellowship in Basic or Translational Research

Sponsored by the Sidney Kimmel Foundation for Cancer Research

"Apoptosis Regulation by Bcl-2 and Raf-1 on Mitochondria"

Richard Todd Reilly, Ph.D.

AACR Research Fellowship in Prevention Research

Sponsored by the Cancer Research Foundation of America

"Antigen-Based Strategy for the Prevention of Breast Cancer"

MOLECULAR GENETICS OF CANCER



Joint Conference of the
American Association for Cancer Research
and the
European Association for Cancer Research



September 9-12, 1997
Hertford College, University of Oxford
Oxford, England

CONFERENCE CHAIRPERSONS

Eric J. Stanbridge / Irvine, CA
Sir Walter Bodmer / Oxford, England

SCIENTIFIC PROGRAM

Keynote Lecture

Richard D. Klausner / Bethesda, MD

Lower Eukaryotes - What they Tell Us About Cancer Genes

Roel Nusse / Stanford, CA

Tian Xu / New Haven, CT

Ronald H. A. Plasterk / Amsterdam, The Netherlands

Joan Massagué / New York, NY

New Approaches to Cloning Tumor Suppressor Genes

Adi Kimchi / Rehovot, Israel

Stanley N. Cohen / Stanford, CA

Additional speakers to be announced

Cell Cycle Genes and Cancer

Paul Nurse / London, England

Gordon Peters / London, England

Charles J. Sherr / Memphis, TN

Xin Lu / London, England

Molecular Analysis of Multistep Progression

Peter Collins / Goteborg, Sweden

Paul Cairns / Baltimore, MD

Helene S. Smith / San Francisco, CA

Transgenic Mouse Models of Cancer

Walter Bodmer / Oxford, England

Terry A. Van Dyke / Chapel Hill, NC

Allan Bradley / Houston, TX

Anton J. M. Berns / Amsterdam, The Netherlands

Molecular Genetics of Cancer of the Cervix

Eric J. Stanbridge / Irvine, CA

Karen H. Vousden / London, England

Garret M. Hampton / La Jolla, CA

*Applicants are encouraged to submit abstracts
for poster presentation.*

Application deadline: June 2, 1997

Information and Application Forms

American Association for Cancer Research

Public Ledger Building, Suite 826

150 South Independence Mall West

Philadelphia, PA 19106-3483 USA

215-440-9300 215-440-9313 (FAX)

e-mail: aacr@aacr.org

AACR Website: <http://www.aacr.org>

European Association for Cancer Research

Cancer Research Laboratory

University of Nottingham

Nottingham NG7 2RD UK

+44-115-951-5114 +44-115-951-5115 (FAX)

e-mail: paul.saunders@nottingham.ac.uk

Sustaining Members

The American Association for Cancer Research is pleased to acknowledge its 1997 Sustaining Members. We are grateful for the generous support derived from this category of membership, which is open to organizations that pay dues and make other significant contributions toward the purposes, activities, and overall mission of the Association. The AACR looks forward to a long and productive partnership with the Major Sustaining Members and regular Sustaining Members listed below.

Major Sustaining Members

Abbott Laboratories
Amgen
Genentech, Inc.
Glaxo Wellcome Oncology
Hoffmann-La Roche Inc.
Janssen Pharmaceutica
Novartis Pharma AG (formerly *CIBA* and *Sandoz Pharmaceuticals Corporation*)
Rhône-Poulenc Rorer
SmithKline Beecham Pharmaceuticals
Wyeth-Ayerst Research
ZENECA Pharmaceuticals

Sustaining Members

ALZA Corporation
ASTA Medica
BASF Bioresearch Corporation
Bayer Corporation
Berlex Biosciences
Bristol-Myers Squibb Oncology
Coulter Corporation
CYTOGEN Corporation
The DuPont Merck Pharmaceutical Company
Eli Lilly and Company
Hoechst Marion Roussel
ILEX™ Oncology Inc.
Kellogg Company
Kirin Brewery Co., Ltd.
Merck Research Laboratories
Oncor, Inc.
Ortho Biotech Inc.
Parke-Davis Pharmaceutical Research, Warner-Lambert Company
The Pezcoller Foundation
Pfizer Central Research
Pharmacia & Upjohn, Inc.
The Procter & Gamble Company
Sanofi Winthrop, Inc.
Schering-Plough Research Institute
Searle
Taiho Pharmaceutical Co., Ltd.
Varian Associates, Inc.
Yamanouchi Pharmaceutical Co., Ltd.



AMERICAN ASSOCIATION FOR CANCER RESEARCH

BENEFITS OF MEMBERSHIP

The American Association for Cancer Research (AACR) is a scientific society consisting of over 11,000 laboratory and clinical cancer researchers. It was founded in 1907 "to facilitate communication and dissemination of knowledge among scientists and others dedicated to the cancer problem; to foster research in cancer and related biomedical sciences; to encourage presentation and discussion of new and important observations in the field; to foster public education, science education, and training; and to advance the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world." Members of the AACR enjoy the following benefits:

- the opportunity to subscribe to AACR's four prestigious journals: *Cancer Research*, *Clinical Cancer Research*, *Cell Growth & Differentiation*, and *Cancer Epidemiology, Biomarkers & Prevention*, at reduced member rates.
 - * ***Cancer Research*** publishes about 6,300 pages per year of timely and significant research in the broad subfields of cancer research. With over 69,000 citations to its articles per year, it is the most highly cited journal in the cancer field and now ranks 16th among 10,000 scientific journals worldwide.
 - * ***Clinical Cancer Research***, a new AACR journal which was launched last year, already has about 4,500 subscribers, and encompasses both clinical and translational research. It publishes exciting clinical trials evaluating new treatments for cancer as well as preclinical studies that will lead to clinical trials.
 - * ***Cell Growth & Differentiation***, the Association's journal covering the molecular biology of cancer, is dedicated to bringing cutting-edge molecular cancer research rapidly to print. With over 2,000 subscribers, this monthly journal has established itself as an important source of significant new data in molecular oncology.
 - * ***Cancer Epidemiology, Biomarkers & Prevention***, which features new findings in cancer epidemiology, risk assessment and carcinogenesis, cancer prevention and control, and biomarkers for cancer detection, became a monthly publication in January 1996.
- the privilege of sponsoring a proffered paper (abstract) for consideration for presentation at the AACR annual meeting; (The AACR annual meeting is attended by more than 6,500 scientists from around the world and is the meeting you can't afford to miss. Scientists consider our annual meeting the most important multidisciplinary cancer meeting which encompasses basic research, clinical cancer research, and the exciting interface area of translational research.)
- an advance copy of the Program and *Proceedings of the American Association for Cancer Research* that contains over 4,000 abstracts of proffered papers presented at the annual meeting;
- reduced registration rates at annual meetings;
- priority notice of small, focussed meetings in the AACR's exciting series of **Special Conferences in Cancer Research**;
- substantially reduced registration rates for Special Conferences;
- opportunities for participation in AACR meetings in North America and abroad with other scientific societies around the world;
- receipt of **AACR Newsletters** and other important announcements;
- early notification of and reduced rates for participation in the **AACR Employment Register**;
- an up-to-date **Directory of Members** containing names and addresses of over 11,000 member researchers in the cancer field;
- the professional benefits of AACR's public education activities concerning funding for cancer research and press coverage of the latest research findings;
- the opportunity to participate in three **Summer Workshops** that foster knowledge in the cancer field for young investigators;
- the facilitation of informal scientific exchange with leading researchers in the cancer field; and
- many more ongoing benefits.

**The Surgery Branch
of The National Cancer Institute Is Seeking
Patients with the Following Malignancies for
Combined Modality or Innovative
Immunotherapy Programs:**

- METASTATIC MELANOMA AND KIDNEY CANCER •
- STAGE II OR LOCALLY ADVANCED BREAST CANCER •
- METASTATIC COLORECTAL CANCER TO THE LIVER •
- LOCOREGIONAL GASTRIC OR PANCREATIC CANCER •
- MESOTHELIOMA, PULMONARY METASTASES, STAGE III A
AND B LUNG CANCER OR ESOPHAGEAL CANCER •
- LOCALIZED SOFT TISSUE SARCOMAS •
- PERITONEAL CARCINOMATOSIS •

*Care for all patients is provided at the clinical center at the
National Institutes of Health in Bethesda, Maryland.*

For more information on cancer programs, please call

(301) 496-1533



A PUBLIC SERVICE ANNOUNCEMENT COURTESY OF THIS PUBLICATION

Hit our Home Page on the World Wide Web!

<http://www.aacr.org>

Our web site features . . .

- **AACR scientific meeting schedule**
- **Table of Contents of AACR journals**
- **Instructions for Authors**
- **Information about AACR Research Fellowships and Travel Awards**

Plus . . . The latest AACR newsletter, and much more!



THE AMERICAN ASSOCIATION FOR CANCER RESEARCH PRESENTS



*An Important Educational Opportunity Primarily for
Predoctoral Students and Postdoctoral Fellows
Pursuing Careers in Basic Cancer Research*

MOLECULAR BIOLOGY AND PATHOLOGY OF NEOPLASIA

(A Workshop Formerly Entitled Histopathobiology of Neoplasia)

The Edward A. Smuckler Memorial Workshop

Supported by a Generous Grant from the National Cancer Institute

Keystone Resort
Keystone, Colorado
July 6-13, 1997

- Intensive training in the histopathology and molecular biology of neoplasia.
- Twenty-eight hours of hands-on laboratory exercises directed by distinguished pathologists.
- An outstanding series of lectures on rapidly developing areas of cancer research by laboratory directors and other prominent investigators.
- Extensive written course materials that will serve as valuable references in the future.
- Waiver of registration fee and partial support for students' and fellows' lodging and subsistence expenses during the workshop.

LABORATORY AND LECTURING FACULTY

Robert Low*, Course Director, University of
Colorado School of Medicine, Denver, CO
Stephen Baird, Veterans Administration Medical
Center, San Diego, CA
Bette DeMasters, University of Colorado School of
Medicine, Denver, CO
Douglas Hanahan, University of California, San
Francisco, CA
Lora A. Hedrick, Johns Hopkins University School of
Medicine, Baltimore, MD
Gary J. Kelloff, National Cancer Institute,
Bethesda, MD
John M. Lehman, Albany College of Medicine,
Albany, NY
Michael W. Lieberman, Baylor College of
Medicine, Houston, TX
Lawrence A. Loeb, University of Washington,
Seattle, WA

Andrea I. McClatchey, Massachusetts Institute of
Technology, Cambridge, MA
Gary J. Miller*, University of Colorado School of
Medicine, Denver, CO
Raymond J. Monnat, University of Washington,
Seattle, WA
Harold L. Moses, Vanderbilt University School of
Medicine, Nashville, TN
Barbara A. Murphy, Vanderbilt University School of
Medicine, Nashville, TN
Stewart Sell, Albany Medical College, Albany, NY
Patricia A. Thomas, University of Iowa Hospital and
Clinics, Iowa City, IA
Ann D. Thor, Northwestern University, Chicago, IL
Frederic M. Waldman*, University of California, San
Francisco, CA

**Member of the Workshop Executive Committee*

APPLICATION DEADLINE: APRIL 30, 1997

Further Information:

American Association for Cancer Research
Public Ledger Building, Suite 826
150 S. Independence Mall West
Philadelphia, PA 19106-3483
Telephone: (215) 440-9300 • FAX: (215) 440-9313
E-mail: AACR@aacr.org

Four Essential Journals from the AACR

Priority reading for over 50 years –
cited more than any other journal
in its field

CANCER RESEARCH

Vol. 57, 1997 (24 issues)
ISSN 0008-5472

Editor-in-Chief:
Carlo M. Croce, M.D.

- State-of-the-art laboratory and clinical investigations
- Advances in Brief
- Selected review articles

AACR members: \$90;
Outside Americas: \$160
Individual nonmembers: \$460;
Outside U.S.: \$550
Institutions: \$685; Outside U.S.: \$815

Institutional subscriptions include a subscription to *Clinical Cancer Research*. Available only as a combined subscription. *Proceedings of the AACR* is included in Individual nonmember and Institutional subscriptions to *Cancer Research*.

A major resource on the
molecular biology of cancer

CELL GROWTH & DIFFERENTIATION

Vol. 8, 1997 (12 issues)
ISSN 1044-9523

Editor-in-Chief:
Joseph R. Nevins, Ph.D.

- Original *in vitro* and *in vivo* studies of the molecular biology of cancer, including normal and abnormal cellular processes
- Research Capsules
- Viewpoints

AACR members: \$60;
Outside Americas: \$90
Individual nonmembers: \$105;
Outside U.S.: \$145
Institutions: \$280; Outside U.S.: \$320

An up-to-the-minute journal
spanning three vital fields

CANCER EPIDEMIOLOGY, BIOMARKERS & PREVENTION

Vol. 6, 1997 (12 issues)
ISSN 1055-9965

Editor-in-Chief:
Pelayo Correa, M.D.

- Original research on causes and prevention of cancer in humans
- Invited editorials
- Selected review articles
- Short communications
- Meeting reports

AACR members: \$55;
Outside Americas: \$85
Individual nonmembers: \$95;
Outside U.S.: \$135
Institutions: \$245; Outside U.S.: \$285

An exciting new forum for clinical
and translational cancer research

CLINICAL CANCER RESEARCH

Vol. 3, 1997 (12 issues)
ISSN 1078-0432

Editor-in-Chief:
John Mendelsohn, M.D.

- Research articles
- Advances in Brief
- Minireviews
- Controversies in Clinical Cancer Research

AACR members: \$50;
Outside Americas: \$80
Individual nonmembers: \$105;
Outside U.S.: \$145
Institutions: \$685; Outside U.S.: \$815

Institutional subscriptions include a subscription to *Cancer Research*. Available only as a combined subscription.

ORDER TODAY!

Members, American Association
for Cancer Research:

To place your order, contact the AACR at
(215) 440-9300; FAX (215) 440-9313.

Members subscribing to any AACR journal automatically receive the *Proceedings of the AACR*.

Institutions: Purchase all four journals and save 15% off the total subscription price, excluding postage outside U.S.
Canada: Add 7% GST to all orders. MD: Add state sales tax.

Nonmembers, contact:

FULCO, Inc.

P.O. Box 3000, Denville, NJ 07834

1-800-875-2997 or (201) 627-2427

FAX (201) 627-5872

